Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 189

1.

Should MMMT still be treated with adjuvant taxane-based combination chemotherapy?

Heinzelmann-Schwarz V, Kind AB, Vetter M, Russell K, Omar S, Schoetzau A, Hoeck K, Fink D, Friedlander ML, Hacker NF.

J Cancer Res Clin Oncol. 2020 Mar;146(3):695-704. doi: 10.1007/s00432-019-03091-y. Epub 2020 Jan 28.

2.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, Ananda S, Anglesio MS, Au-Yeung G, Böhm M, Bowtell DDL, Brand A, Chenevix-Trench G, Christie M, Chiew YE, Churchman M, DeFazio A, Demeo R, Dudley R, Fairweather N, Fedele CG, Fereday S, Fox SB, Gilks CB, Gourley C, Hacker NF, Hadley AM, Hendley J, Ho GY, Hughes S, Hunstman DG, Hunter SM, Jobling TW, Kalli KR, Kaufmann SH, Kennedy CJ, Köbel M, Le Page C, Li J, Lupat R, McNally OM, McAlpine JN, Mes-Masson AM, Mileshkin L, Provencher DM, Pyman J, Rahimi K, Rowley SM, Salazar C, Samimi G, Saunders H, Semple T, Sharma R, Sharpe AJ, Stephens AN, Thio N, Torres MC, Traficante N, Xing Z, Zethoven M, Antill YC, Scott CL, Campbell IG, Gorringe KL.

Nat Commun. 2019 Sep 2;10(1):3935. doi: 10.1038/s41467-019-11862-x.

3.

Response to Re: 'Neoadjuvant chemotherapy for advanced ovarian cancer. Who really benefits?'

Hacker NF.

Aust N Z J Obstet Gynaecol. 2018 Dec;58(6):E26-E27. doi: 10.1111/ajo.12925. No abstract available.

PMID:
30536513
4.

Impact of the new FIGO 2013 classification on prognosis of stage I epithelial ovarian cancers.

Montavon Sartorius C, Mirza U, Schötzau A, Mackay G, Fink D, Hacker NF, Heinzelmann-Schwarz V.

Cancer Manag Res. 2018 Oct 17;10:4709-4718. doi: 10.2147/CMAR.S174777. eCollection 2018.

5.

ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.

Montavon Sartorius C, Schoetzau A, Kettelhack H, Fink D, Hacker NF, Fedier A, Jacob F, Heinzelmann-Schwarz V.

PLoS One. 2018 Mar 29;13(3):e0195213. doi: 10.1371/journal.pone.0195213. eCollection 2018.

6.

Improving attendance to genetic counselling services for gynaecological oncology patients.

Pokharel HP, Hacker NF, Andrews L.

Gynecol Oncol Res Pract. 2018 Jan 10;5:2. doi: 10.1186/s40661-018-0059-z. eCollection 2018.

7.

Neoadjuvant chemotherapy for advanced epithelial ovarian cancer. Who really benefits?

Hacker NF.

Aust N Z J Obstet Gynaecol. 2017 Dec;57(6):585-587. doi: 10.1111/ajo.12737. No abstract available.

PMID:
29210052
8.

Hereditary gynaecologic cancers in Nepal: a proposed model of care to serve high risk populations in developing countries.

Pokharel HP, Hacker NF, Andrews L.

Hered Cancer Clin Pract. 2017 Sep 18;15:12. doi: 10.1186/s13053-017-0072-y. eCollection 2017.

9.

Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma.

Anugraham M, Jacob F, Everest-Dass AV, Schoetzau A, Nixdorf S, Hacker NF, Fink D, Heinzelmann-Schwarz V, Packer NH.

Mol Oncol. 2017 Nov;11(11):1595-1615. doi: 10.1002/1878-0261.12134. Epub 2017 Sep 29.

10.

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Henry CE, Emmanuel C, Lambie N, Loo C, Kan B, Kennedy CJ, de Fazio A, Hacker NF, Ford CE.

Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.

11.

Naturally occurring anti-glycan antibodies binding to Globo H-expressing cells identify ovarian cancer patients.

Pochechueva T, Alam S, Schötzau A, Chinarev A, Bovin NV, Hacker NF, Jacob F, Heinzelmann-Schwarz V.

J Ovarian Res. 2017 Feb 10;10(1):8. doi: 10.1186/s13048-017-0305-8.

12.
13.

Surgery for advanced epithelial ovarian cancer.

Hacker NF, Rao A.

Best Pract Res Clin Obstet Gynaecol. 2017 May;41:71-87. doi: 10.1016/j.bpobgyn.2016.10.007. Epub 2016 Oct 20. Review.

PMID:
27884789
14.

Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.

Pochechueva T, Chinarev A, Schoetzau A, Fedier A, Bovin NV, Hacker NF, Jacob F, Heinzelmann-Schwarz V.

PLoS One. 2016 Oct 20;11(10):e0164230. doi: 10.1371/journal.pone.0164230. eCollection 2016.

15.

Changing patterns of referrals and outcomes of genetic participation in gynaecological-oncology multidisciplinary care.

Pokharel HP, Hacker NF, Andrews L.

Aust N Z J Obstet Gynaecol. 2016 Dec;56(6):633-638. doi: 10.1111/ajo.12504. Epub 2016 Aug 17.

PMID:
27530527
16.

Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review.

Hacker NF, Rao A.

Gynecol Oncol Res Pract. 2016 Jun 17;3:7. doi: 10.1186/s40661-016-0028-3. eCollection 2016. Review.

17.

Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer.

Henry CE, Llamosas E, Djordjevic A, Hacker NF, Ford CE.

Oncogenesis. 2016 May 30;5(5):e226. doi: 10.1038/oncsis.2016.32.

18.

Improved Detection Rate of Ovarian Cancer Using a 2-Step Triage Model of the Risk of Malignancy Index and Expert Sonography in an Outpatient Screening Setting.

Manegold-Brauer G, Buechel J, Knipprath-Mészaros A, Schoetzau A, Hacker NF, Tercanli S, Lapaire O, Heinzelmann-Schwarz V.

Int J Gynecol Cancer. 2016 Jul;26(6):1062-9. doi: 10.1097/IGC.0000000000000718.

PMID:
27177281
19.

Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.

Moran-Jones K, Gloss BS, Murali R, Chang DK, Colvin EK, Jones MD, Yuen S, Howell VM, Brown LM, Wong CW, Spong SM, Scarlett CJ, Hacker NF, Ghosh S, Mok SC, Birrer MJ, Samimi G.

Oncotarget. 2015 Dec 29;6(42):44551-62. doi: 10.18632/oncotarget.6082.

20.

Changing Trends in Vulvar Cancer Incidence and Mortality Rates in Australia Since 1982.

Barlow EL, Kang YJ, Hacker NF, Canfell K.

Int J Gynecol Cancer. 2015 Nov;25(9):1683-9. doi: 10.1097/IGC.0000000000000547.

PMID:
26495761
21.

Cancer of the vagina.

Hacker NF, Eifel PJ, van der Velden J.

Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S84-7. doi: 10.1016/j.ijgo.2015.06.003. No abstract available.

22.

Cancer of the vulva.

Hacker NF, Eifel PJ, van der Velden J.

Int J Gynaecol Obstet. 2015 Oct;131 Suppl 2:S76-83. doi: 10.1016/j.ijgo.2015.06.002. No abstract available. Erratum in: Int J Gynaecol Obstet. 2016 Mar;132(3):365.

23.

Optimal uptake rates for initial treatments for cervical cancer in concordance with guidelines in Australia and Canada: Results from two large cancer facilities.

Kang YJ, O'Connell DL, Tan J, Lew JB, Demers A, Lotocki R, Kliewer EV, Hacker NF, Jackson M, Delaney GP, Barton M, Canfell K.

Cancer Epidemiol. 2015 Aug;39(4):600-11. doi: 10.1016/j.canep.2015.04.009. Epub 2015 May 23.

PMID:
26004990
24.

Staging for vulvar cancer.

Hacker NF, Barlow EL.

Best Pract Res Clin Obstet Gynaecol. 2015 Aug;29(6):802-11. doi: 10.1016/j.bpobgyn.2015.01.004. Epub 2015 Mar 4. Review.

PMID:
25842047
25.

Is quantification of lymphovascular space invasion useful in stage 1B2 cervical carcinomas?

Scurry J, Hacker NF, Barlow E, Friedlander M, Jackson M.

J Obstet Gynaecol. 2015 May;35(4):377-81. doi: 10.3109/01443615.2014.958448. Epub 2014 Oct 27.

PMID:
25347062
26.

Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.

Jacob F, Hitchins MP, Fedier A, Brennan K, Nixdorf S, Hacker NF, Ward R, Heinzelmann-Schwarz VA.

BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.

27.

The glycosphingolipid P₁ is an ovarian cancer-associated carbohydrate antigen involved in migration.

Jacob F, Anugraham M, Pochechueva T, Tse BW, Alam S, Guertler R, Bovin NV, Fedier A, Hacker NF, Huflejt ME, Packer N, Heinzelmann-Schwarz VA.

Br J Cancer. 2014 Oct 14;111(8):1634-45. doi: 10.1038/bjc.2014.455. Epub 2014 Aug 28.

28.

Effects of access to and treatment in specialist facilities on survival from epithelial ovarian cancer in Australian women: a data linkage study.

Tracey E, Hacker NF, Young J, Armstrong BK.

Int J Gynecol Cancer. 2014 Sep;24(7):1232-40. doi: 10.1097/IGC.0000000000000213.

PMID:
25153678
29.

Reliable in vitro studies require appropriate ovarian cancer cell lines.

Jacob F, Nixdorf S, Hacker NF, Heinzelmann-Schwarz VA.

J Ovarian Res. 2014 Jun 7;7:60. doi: 10.1186/1757-2215-7-60. eCollection 2014. Review.

30.

Methylation-capture and Next-Generation Sequencing of free circulating DNA from human plasma.

Warton K, Lin V, Navin T, Armstrong NJ, Kaplan W, Ying K, Gloss B, Mangs H, Nair SS, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

BMC Genomics. 2014 Jun 15;15:476. doi: 10.1186/1471-2164-15-476.

31.

Quality of life after complete lymphadenectomy for vulvar cancer: do women prefer sentinel lymph node biopsy?

Farrell R, Gebski V, Hacker NF.

Int J Gynecol Cancer. 2014 May;24(4):813-9. doi: 10.1097/IGC.0000000000000101.

PMID:
24662129
32.

A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker.

Heinzelmann-Schwarz VA, Nixdorf S, Valadan M, Diczbalis M, Olivier J, Otton G, Fedier A, Hacker NF, Scurry JP.

Int J Mol Med. 2014 Apr;33(4):784-94. doi: 10.3892/ijmm.2014.1659. Epub 2014 Feb 14. Review.

33.

Sexuality and body image following treatment for early-stage vulvar cancer: a qualitative study.

Barlow EL, Hacker NF, Hussain R, Parmenter G.

J Adv Nurs. 2014 Aug;70(8):1856-66. doi: 10.1111/jan.12346. Epub 2014 Jan 17.

PMID:
24433533
34.

ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer.

Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, Sutherland RL, Clark SJ, Samimi G.

Mol Cancer. 2014 Jan 6;13:3. doi: 10.1186/1476-4598-13-3.

35.

State of the art of surgery in advanced epithelial ovarian cancer.

Hacker NF.

Ann Oncol. 2013 Dec;24 Suppl 10:x27-32. doi: 10.1093/annonc/mdt465. Review. No abstract available.

36.

Primary surgical management with tailored adjuvant radiation for stage IB2 cervical cancer.

Hacker NF, Barlow EL, Scurry J, Gebski V, Farrell R, Robertson G, Friedlander ML, Jackson M.

Obstet Gynecol. 2013 Apr;121(4):765-72. doi: 10.1097/AOG.0b013e3182887836.

PMID:
23635676
37.

Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines.

Jacob F, Guertler R, Naim S, Nixdorf S, Fedier A, Hacker NF, Heinzelmann-Schwarz V.

PLoS One. 2013;8(3):e59180. doi: 10.1371/journal.pone.0059180. Epub 2013 Mar 15. Review.

38.

Data set for reporting of endometrial carcinomas: recommendations from the International Collaboration on Cancer Reporting (ICCR) between United Kingdom, United States, Canada, and Australasia.

McCluggage WG, Colgan T, Duggan M, Hacker NF, Mulvany N, Otis C, Wilkinson N, Zaino RJ, Hirschowitz L.

Int J Gynecol Pathol. 2013 Jan;32(1):45-65. doi: 10.1097/PGP.0b013e31825d808b. Review.

PMID:
23202790
39.

Cancer of the vagina.

Hacker NF, Eifel PJ, van der Velden J.

Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S97-9. doi: 10.1016/S0020-7292(12)60022-8. No abstract available.

PMID:
22999510
40.

Cancer of the vulva.

Hacker NF, Eifel PJ, van der Velden J.

Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S90-6. doi: 10.1016/S0020-7292(12)60021-6. No abstract available.

PMID:
22999509
41.

Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.

Jacob F, Ukegjini K, Nixdorf S, Ford CE, Olivier J, Caduff R, Scurry JP, Guertler R, Hornung D, Mueller R, Fink DA, Hacker NF, Heinzelmann-Schwarz VA.

PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.

42.

Women in Western societies. Foreword.

Hacker NF.

Best Pract Res Clin Obstet Gynaecol. 2012 Jun;26(3):291-2. doi: 10.1016/j.bpobgyn.2012.01.003. Epub 2012 Feb 18. No abstract available.

PMID:
22342151
43.

Quality control in ovarian cancer surgery.

Hacker NF.

Ann Oncol. 2011 Dec;22 Suppl 8:viii19-viii22. doi: 10.1093/annonc/mdr517. Review.

44.

TLE3 expression is associated with sensitivity to taxane treatment in ovarian carcinoma.

Samimi G, Ring BZ, Ross DT, Seitz RS, Sutherland RL, O'Brien PM, Hacker NF, Huh WK.

Cancer Epidemiol Biomarkers Prev. 2012 Feb;21(2):273-9. doi: 10.1158/1055-9965.EPI-11-0917. Epub 2011 Dec 22.

45.

Integrative genome-wide expression and promoter DNA methylation profiling identifies a potential novel panel of ovarian cancer epigenetic biomarkers.

Gloss BS, Patterson KI, Barton CA, Gonzalez M, Scurry JP, Hacker NF, Sutherland RL, O'Brien PM, Clark SJ.

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.

PMID:
22155104
46.

Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer.

Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Gynecol Oncol. 2012 Mar;124(3):582-8. doi: 10.1016/j.ygyno.2011.11.026. Epub 2011 Nov 22.

PMID:
22115852
47.

MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.

Byrne JA, Maleki S, Hardy JR, Gloss BS, Murali R, Scurry JP, Fanayan S, Emmanuel C, Hacker NF, Sutherland RL, Defazio A, O'Brien PM.

BMC Cancer. 2010 Sep 17;10:497. doi: 10.1186/1471-2407-10-497.

48.

Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.

Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.

Br J Cancer. 2010 Jan 5;102(1):87-96. doi: 10.1038/sj.bjc.6605429. Epub 2009 Nov 24.

49.

Reasons for improved survival from ovarian cancer in New South Wales, Australia, between 1980 and 2003: implications for cancer control.

Tracey EA, Roder DM, Francis J, Zorbas HM, Hacker NF, Bishop JF.

Int J Gynecol Cancer. 2009 May;19(4):591-9. doi: 10.1111/IGC.0b013e3181a3a436.

PMID:
19509555
50.

Revised FIGO staging for carcinoma of the vulva.

Hacker NF.

Int J Gynaecol Obstet. 2009 May;105(2):105-6. doi: 10.1016/j.ijgo.2009.02.011. Epub 2009 Mar 28. No abstract available.

PMID:
19329116

Supplemental Content

Loading ...
Support Center